Last updated: February 13, 2026
What is the drug associated with NDC 83324-0318?
NDC 83324-0318 corresponds to Sotagliflozin, an investigational sodium-glucose cotransporter 1 (SGLT1) and 2 (SGLT2) inhibitor. It is developed for managing type 2 diabetes mellitus (T2DM). The drug was under development by Sanofi/Regeneron but has not received FDA approval.
What is the current market environment for Sotagliflozin?
Sotagliflozin entered clinical trials but faced mixed results and regulatory hurdles. Its global market potential is limited due to lack of regulatory approval and competition from already approved drugs like Januvia (sitagliptin), Invokana (canagliflozin), and Farxiga (dapagliflozin).
What is the estimated market size?
The global market for SGLT inhibitors was valued at approximately $8 billion in 2022 and is projected to reach around $15 billion by 2027, growing at a compound annual growth rate (CAGR) of roughly 12%.
In the United States, the total sales for SGLT2 inhibitors alone exceeded $4 billion in 2022, indicative of high adoption rates among T2DM patients. The inclusion of compounds with dual SGLT1/2 activity like Sotagliflozin generally accounts for smaller market shares due to competition and regulatory status.
What are the competitive advantages and challenges?
Advantages:
- Dual SGLT1/2 inhibition could potentially improve gut glucose absorption and renal glucose excretion.
- Potential for improved glycemic control when combined with other therapies.
Challenges:
- Pending or lack of regulatory approval limits commercial opportunities.
- Side effect profile, including risks of ketoacidosis and urinary tract infections, is similar to other SGLT2 inhibitors but needs optimized safety data.
- Market entrants like Invokana and Farxiga have established safety profiles and market penetration.
What are the price projections?
As of 2023, no approved pricing exists for Sotagliflozin due to its investigational status. Historically, branded SGLT2 inhibitors are priced between $500 and $700 monthly per patient in the United States.
Projected pricing scenarios:
- Low-end: $400/month if approved as a generic or biosimilar market entry reduces costs.
- Mid-range: $600/month aligning with existing branded SGLT2 therapies.
- High-end: $700/month if marketed with added benefits or in specialized niches.
The actual price depends on regulatory outcomes, manufacturing costs, competitive positioning, and payer negotiations.
What is the regulatory outlook?
- In 2019, the European Medicines Agency (EMA) rejected the drug citing insufficient efficacy data.
- The FDA has not approved Sotagliflozin, citing safety concerns and competitive market dynamics.
- Future approvals hinge on submission of robust Phase 3 data confirming additional benefits over existing therapies.
What are the potential market entry timelines?
- With successful completion of late-stage clinical trials and regulatory filings, approval could occur between 2024 and 2026.
- Market penetration may be slow due to established competitors and safety/tolerability considerations.
Summary of key data points
| Aspect |
Data |
Source |
| Estimated global SGLT market size (2022) |
$8 billion |
[1] |
| Projected market size (2027) |
$15 billion |
[1] |
| U.S. SGLT2 inhibitor sales (2022) |
>$4 billion |
[2] |
| Typical monthly price for branded SGLT2 inhibitors |
$500–$700 |
[3] |
Key Takeaways
- NDC 83324-0318 (Sotagliflozin) remains investigational; no current commercial pricing exists.
- Designed to compete within an $8-15 billion global SGLT inhibitor market projected to grow at 12% annually through 2027.
- Market entry depends on successful clinical trials, regulatory approval, and safety profile validation.
- Pricing is expected within the range of existing branded SGLT2 inhibitors, adjusted based on regulatory and competitive environment.
- Entrenched competitors and safety concerns represent primary hurdles.
Frequently Asked Questions
1. Will Sotagliflozin likely achieve FDA approval?
Approval depends on the outcomes of continued clinical trials. While preliminary data showed promise, safety concerns and comparative efficacy issues need resolution.
2. How does Sotagliflozin compare to existing SGLT2 inhibitors?
It offers dual SGLT1/2 inhibition which could provide additional benefits, such as delayed glucose absorption. However, safety profiles and proven efficacy remain under scrutiny.
3. What factors influence its future price?
Regulatory approval, manufacturing costs, market competition, and negotiated payer prices primarily determine its price upon launch.
4. When might Sotagliflozin enter the market?
Approval could occur within 2 to 4 years if late-phase clinical trials are successful and regulatory bodies approve the drug.
5. What strategic considerations should investors or pharma companies evaluate?
Drug efficacy, safety profiles, regulatory trajectory, competitive landscape, and manufacturing scalability are critical for making informed decisions.
Citations
[1] MarketsandMarkets. (2023). SGLT inhibitors market forecast.
[2] IQVIA. (2022). U.S. pharmaceutical sales data.
[3] Drugs.com. (2023). Pricing and reimbursement details for branded SGLT2 inhibitors.
